A simple three-tier risk model separated transplant recipients by skin cancer risk nearly twelvefold

The edition in brief

Today's dermatology edition opens on a retrospective Karolinska cohort (JID, 22 September) of 395 solid organ transplant recipients followed for up to 13 years. Over a third, 38%, developed invasive skin cancer. Recipients graded intermediate or high risk at baseline had about 6-fold and 12-fold higher hazards of invasive skin cancer than low-risk recipients, and higher all-cause mortality — support for scheduling follow-up by risk rather than by a single interval. The PEDISTAD registry (JAAD, 21 September) followed 500 children under 12 with moderate-to-severe atopic dermatitis: EASI improved most with dupilumab in both White and non-White children, with lower exposure-adjusted adverse event rates than cyclosporine. It is observational, so treatment groups were not comparable. On regulation, the FDA approved a supplemental application for abrocitinib (Cibinqo, Pfizer) on 2 September; the record does not say what the supplement changed, and it should not be read as a new indication. The edition closes on a JAAD continuing-education review (21 September) on antibiotic prophylaxis for skin surgery: most excisions and Mohs procedures are clean, low-risk operations that need no systemic antibiotic, and prophylaxis should be kept for defined cardiac, prosthetic and immunosuppressed indications. The pearl is on writing the transplant patient's risk tier where every clinician will see it.